BRITISH JOURNAL OF DERMATOLOGY

BRITISH JOURNAL OF DERMATOLOGY Journal

publication venue for

Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials. 190:836-845. 2024
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study. 189:392-399. 2023
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. 188:22-31. 2023
The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies 2020
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. 181:733-742. 2019
Continued treatment with secukinumab is associated with high retention or regain of response. 182:67-75. 2019
Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. 170:672-680. 2014
Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. 163:334-339. 2010
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial 2023
Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study 2021
Early trends of disease improvement in adult patients with atopic dermatitis treated with dupilumab: real-world data from the PROSE registry 2021

International Standard Serial Number (ISSN)

0007-0963

Electronic International Standard Serial Number (EISSN)

1365-2133